TREAT TO TARGET FOR CROHN’S DISEASE WITH ADALIMUMAB TREATMENT IS COST EFFECTIVE OVER 48 WEEKS: AN ECONOMIC ASSESSMENT OF THE CALM TRIAL

Remo Panaccione  ¹     Jean-Frederic Colombel  ²     Peter Bossuyt  ³     Milan Lukas  ⁴     Filip Baert  ⁵     T. Vanásek  ⁶     Ahmet Danalıoğlu  ⁷     Gottfried Novacek     Alessandro Armuzzi     Walter Reinisch     Scott Johnson     Matthew Davis     Ezequiel Neimark     Joel Petersson     Anne M. Robinson     Roopal B Thakkar     Wan-Ju Lee     Martha Skup    
¹ University of Calgary,Calgary,Canada
² Icahn School of Medicine at Mount Sinai,New York,United States of America
³ Imelda General Hospital,Bonheiden,Belgium
⁴ Charles University,Prague,Czech Republic
⁵ AZ Delta Roeselare-Menen,Menen,Belgium
⁶ Hepato-Gastroenterologie HK, s.r.o.,Hradec Králové,Czech Republic
⁷ Bezmialem Vakif University,İst

Conference
25th UEG Week 2017

Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)